JPH083053A - Therapeutic agent for steroid dermatosis and its production - Google Patents
Therapeutic agent for steroid dermatosis and its productionInfo
- Publication number
- JPH083053A JPH083053A JP6134675A JP13467594A JPH083053A JP H083053 A JPH083053 A JP H083053A JP 6134675 A JP6134675 A JP 6134675A JP 13467594 A JP13467594 A JP 13467594A JP H083053 A JPH083053 A JP H083053A
- Authority
- JP
- Japan
- Prior art keywords
- therapeutic agent
- tea
- tea leaves
- steroid
- water
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
- Compounds Of Unknown Constitution (AREA)
Abstract
Description
【０００１】[0001]
【産業上の利用分野】本発明は、皮膚疾患治療剤、特に
ステロイド皮膚症に有効な治療剤及びこの製造方法に関
する。TECHNICAL FIELD The present invention relates to a therapeutic agent for skin diseases, particularly a therapeutic agent effective for steroid dermatosis, and a method for producing the same.
【０００２】[0002]
【従来の技術】これまでに各種の抗炎症皮膚剤が開発さ
れてきたが、取り分けステロイド剤（副腎皮質ホルモン
剤）の外用剤が開発されてからは、その劇的でかつ速効
性に優れた薬理効果により皮膚科領域における治療に革
命的な変化がもたらされ、このステロイド外用剤は、現
在でも様々な皮膚疾患に用いられている。しかしなが
ら、このステロイド外用剤は、上記のように優れた薬理
効果を持つ反面、長期間使用するとステロイド皮膚症な
どの副作用を引き起こし、さらにステロイド外用剤を使
用しなければならなくなる悪循環に陥り、やがてステロ
イド剤依存状態となってしまうといった問題も抱えてい
た。特に、皮膚に直接塗布する場合には、病変部からス
テロイド剤が吸収されて全身的副作用を起こす危険もあ
った。2. Description of the Related Art Various anti-inflammatory skin agents have been developed so far, but since the topical steroid preparations (corticosteroids) have been developed, they have been dramatically and rapidly effective. The pharmacological effect has brought about a revolutionary change in the treatment in the dermatological field, and this steroid external preparation is still used for various skin diseases. However, while this external preparation for steroids has excellent pharmacological effects as described above, it causes side effects such as steroid dermatosis when used for a long period of time, and further falls into a vicious circle in which external preparations for steroids must be used. I also had the problem of becoming drug dependent. In particular, when it is directly applied to the skin, there is a risk that the steroid drug may be absorbed from the lesion and systemic side effects may occur.
【０００３】また、本来ステロイド剤は、皮膚疾患ばか
りでなく、血液疾患、膠原病，ぜんそくなどのアレルギ
ー，ショック、ネフローゼ、脳浮腫や神経変性疾患など
の神経疾患、肺線維症などの呼吸器疾患などの治療剤と
しても極めて有用である。ところが、通常大量に投与さ
れるため、いったん使用し始めると途中で投与を中止す
ることができなくなり、様々な副作用を併発する危険が
ある他、やはりステロイド皮膚症を引き起こすことも多
かった。In addition to dermatological diseases, originally steroids are allergic to blood diseases, collagen diseases, asthma, shock, nephrosis, neurological diseases such as cerebral edema and neurodegenerative diseases, and respiratory diseases such as pulmonary fibrosis. It is also extremely useful as a therapeutic agent. However, since it is usually administered in a large amount, it is impossible to discontinue the administration once it is started to be used, and there is a risk of causing various side effects as well as steroid dermatosis in many cases.
【０００４】ところで、このようなステロイド皮膚症を
治療するには、ステロイド剤の使用量を徐々に減らすと
ともに、有用な治療剤を用いて治療するのが望ましい
が、上記のようにステロイド皮膚症患者は、皮膚疾患や
薬剤の服用により皮膚乃至体全体が弱っていることが多
いため、薬理効果に優れていることは勿論であるが、人
体に対してより安全性が高く、安心して長期間使用する
ことができる治療剤が望まれる。しかしながら、従来、
このようなステロイド皮膚症治療剤は開示されていなか
った。Incidentally, in order to treat such steroid dermatosis, it is desirable to gradually reduce the amount of steroid used and to treat with a useful therapeutic agent. Is often weakened to the skin or the whole body due to skin diseases or taking drugs, and is of course superior in its pharmacological effect, but it is safer for the human body and can be used safely for a long period of time. A therapeutic agent that can do is desired. However, conventionally,
Such a therapeutic agent for steroid dermatosis has not been disclosed.
【０００５】一方、茶類に関して言えば、例えば本発明
者らが特開平３−２５８７２６で開示しているように、
茶の水溶性タンニン類がヒスタミン遊離抑制作用を有
し、特に抗Ｉ型アレルギー剤として有用であることは確
かめられている。ところが、本願発明が目的とするとこ
ろの上記ステロイド皮膚症治療に茶抽出物が適用可能で
あるという発想は、従来無く何等の示唆もされていなか
った。On the other hand, as for teas, for example, as disclosed by the present inventors in Japanese Patent Laid-Open No. 3-258726,
It has been confirmed that water-soluble tannins of tea have a histamine release inhibitory action and are particularly useful as anti-type I allergic agents. However, the idea that the tea extract can be applied to the treatment of steroid dermatosis, which is the object of the present invention, has not been suggested at all in the past.
【０００６】[0006]
【発明が解決しようとする課題】そこで本発明者らは、
上記ステロイド皮膚症に対する治療剤を開発すべく、茶
類の古くから日常的に飲用されている安全性とその薬理
効果とに着目し、各種茶乃至茶葉からステロイド皮膚症
治療剤及びその製造方法を得んとしたものである。SUMMARY OF THE INVENTION Accordingly, the present inventors
In order to develop a therapeutic agent for the above steroid dermatosis, focusing on the safety and its pharmacological effect of teas that have been ingested daily since ancient times, a therapeutic agent for steroid dermatosis from various teas or tea leaves and a method for producing the same are provided. It is a good thing.
【０００７】[0007]
【課題を解決するための手段】上記課題を解決するため
の本発明のステロイド皮膚症治療剤は、茶抽出物、好ま
しくは水乃至熱水抽出物、特に好ましくは５０乃至１０
０℃の温水で抽出して得られた茶抽出物を有効成分とす
るものであり、ステロイド皮膚症疾患状態にある皮膚に
対して保温及び保湿効果、止痒効果、表皮肥厚の正常
化、苔癬化状態の正常化および抗炎症効果を発揮し、か
つ安全性も高いので、ステロイド皮膚症治療剤として極
めて有用である。The therapeutic agent for steroid dermatosis of the present invention for solving the above problems is a tea extract, preferably water to hot water extract, particularly preferably 50 to 10
A tea extract obtained by extraction with warm water at 0 ° C is used as an active ingredient, and has heat-retaining and moisturizing effects, antipruritic effect, normalization of epidermal thickening, and moss on skin with steroid dermatosis disease state. It is extremely useful as a therapeutic agent for steroid dermatosis because it exhibits normalization of the symptomatic state and anti-inflammatory effect and is highly safe.
【０００８】上記茶は、発酵茶、半発酵茶又は未発酵
茶、好ましくは烏龍茶類であり、特に茶緑葉を日光に晒
した後、室温下で茶葉水分の３０〜５０％を除き、これ
を数時間攪拌し、釜でいり、揉みながら乾燥させた茶葉
であるのが好ましい。なお、烏龍茶としては、各種半発
酵茶およびその加工品が使用可能である。The above-mentioned tea is fermented tea, semi-fermented tea or unfermented tea, preferably oolong tea. Particularly, after exposing the green tea leaves to sunlight, 30 to 50% of the water content of the tea leaves is removed at room temperature, and this tea is removed. It is preferable that the tea leaves are dried while stirring for several hours, roasting in a pot and kneading. As oolong tea, various semi-fermented teas and processed products thereof can be used.
【０００９】上記茶の抽出物の主たる有効成分は、茶タ
ンニン類、例えば烏龍茶タンニン（ウーロン・タンニ
ン）を主成分とするものである。この茶タンニン類の組
成としては、ポリフェノール（Flavan-3-ols）例えばカ
テキン，エピカテキン、エピカテキンガレート，エピガ
ロカテキンガレートなどからなる。The main active ingredient of the tea extract is mainly composed of tea tannins, for example, oolong tea tannin (oolong tannin). The composition of the tea tannins includes polyphenols (Flavan-3-ols) such as catechin, epicatechin, epicatechin gallate, and epigallocatechin gallate.
【００１０】上記ステロイド皮膚症治療剤の製造方法と
しては、発酵茶葉、半発酵茶葉又は未発酵茶葉を乾燥し
て得られた茶葉、例えば自然乾燥させて茶葉中の３０〜
５０％茶葉水分を除き、得られた乾燥茶葉を水乃至熱
水、好ましくは５０乃至１００℃の脱イオン水で抽出
し、抽出物を濾過して不溶物を除いた後、好ましくはこ
の濾過液を茶タンニン類を安定化させるために例えば適
宜量のビタミンＣを加えて低酸性域に抽出液を調整し、
これを４０〜６０℃で減圧濃縮して濃縮液とするか、或
いは濾過液を乾燥させて乾燥粉末とする。As the method for producing the above-mentioned therapeutic agent for steroid dermatosis, tea leaves obtained by drying fermented tea leaves, semi-fermented tea leaves or unfermented tea leaves, for example, 30 to 30% of the tea leaves after naturally dried.
After removing 50% of the water content of the tea leaves, the resulting dried tea leaves are extracted with water or hot water, preferably deionized water at 50 to 100 ° C., the extract is filtered to remove insolubles, and then this filtrate is preferably used. In order to stabilize the tea tannins, for example, an appropriate amount of vitamin C is added to adjust the extract to a low acid region,
This is concentrated under reduced pressure at 40 to 60 ° C to obtain a concentrated liquid, or the filtrate is dried to obtain a dry powder.
【００１１】ステロイド皮膚症の製造方法のさらに好ま
しい一例は、烏龍茶葉を自然乾燥させて約３０〜５０％
の水分を除き、ついで数時間攪拌を行った後、釜で茶葉
をいり、揉みながら再び乾燥させて得られた烏龍茶葉を
約１０〜２０倍量の約５０〜１００℃の脱イオン水で約
５〜３０分間抽出し、この抽出物を濾過して不溶物を除
去した後、適宜量のアスコルビン酸を加えてＰＨ５．０
程度に調製し、これを約４０〜６０℃で減圧濃縮してＢ
ｒｉｘ約１０〜２０の濃縮液とするか、或いはさらに乾
燥させて乾燥粉末とする。A further preferred example of the method for producing steroid dermatosis is as follows: Oolong tea leaves are naturally dried to about 30-50%.
After removing the water content and stirring for several hours, put the tea leaves in a kettle and dry again while rubbing the oolong tea leaves with about 10 to 20 times the amount of deionized water at about 50 to 100 ° C. After extracting for 5 to 30 minutes and removing the insoluble matter by filtering this extract, an appropriate amount of ascorbic acid is added to pH 5.0.
To about 40 ° C to 60 ° C under reduced pressure and concentrated to B
The concentration of rix is about 10 to 20 or is further dried to obtain a dry powder.
【００１２】また、本発明のステロイド皮膚症治療剤
は、上記のように乾燥粉末としたものをそのまま湯浴用
として湯に溶かして用いることもできるが、そのほか適
当な液体単体に溶解させるか若しくは分散させるか又は
適当な粉末単体と混合するか若しくはこれに吸着させ、
所要の場合はさらにこれらに賦形剤、結合剤，崩壊剤，
滑沢剤，安定剤，矯味矯臭剤等を添加するなどして、ハ
ップ剤、軟こう剤、注射剤若しくは坐薬などによる非経
口投与用として、或いは錠剤、カプセル剤、か粒剤、散
剤若しくはシロップ剤などによる経口投与用としても用
いることができる。Further, the steroid dermatosis therapeutic agent of the present invention can be used as a dry powder as described above by dissolving it in hot water as it is, or by dissolving or dispersing it in a suitable liquid simple substance. Or mixed with a suitable powder or adsorbed on it,
If necessary, these may be further added with excipients, binders, disintegrants,
Addition of lubricants, stabilizers, flavoring agents, etc., for parenteral administration such as suppositories, ointments, injections or suppositories, or tablets, capsules, granules, powders or syrups. It can also be used for oral administration such as.
【００１３】本発明のステロイド皮膚症治療剤の使用量
は、使用方法、症状或いは年齢によっても異なるが、例
えば乾燥粉末状のステロイド皮膚症治療剤を湯に溶かし
て患部の湯浴用とする場合、通常成人に対してＢｒｉｘ
約０．０２以上、好ましくは約０．０２〜０．５に希釈
するのが良い。The amount of the therapeutic agent for steroid dermatosis of the present invention varies depending on the method of use, symptom or age. For example, when the therapeutic agent for steroid dermatosis in a dry powder is dissolved in hot water to be used in a hot water bath of an affected area, Brix for normal adults
It may be diluted to about 0.02 or more, preferably about 0.02 to 0.5.
【００１４】[0014]
（ステロイド皮膚症治療剤の製造方法）烏龍茶葉を約４
０％の水分を除く程度に自然乾燥させた後、数時間攪拌
を行い、釜でいり、揉みながら再び乾燥させて得られた
乾燥烏龍茶葉を１５倍量の９０℃の脱イオン水にて１５
分間抽出し、圧搾して得られた搾汁を集め、これを濾過
して不溶物を除去し、得られた濾過液にビタミンＣを加
えてｐＨ５．３〜５．６に調製してから、真空度７２０
ｍｍＨｇ、温度４０℃にて、Ｂｒｉｘ１５まで濃縮し、
この濃縮液を乾燥させて乾燥粉末を得た。乾燥粉末の収
率は、乾燥烏龍茶葉に対して約１９．６重量％であっ
た。(Manufacturing method of steroid dermatosis therapeutic agent) Oolong tea leaves about 4
After air-drying to remove 0% of water, stir for several hours, put in a pot and dry again while rubbing to obtain dried oolong tea leaves with 15 times amount of 90 ° C. deionized water.
Extracted for a minute, squeezed to obtain a juice, which was filtered to remove insoluble matter, and vitamin C was added to the obtained filtrate to adjust the pH to 5.3 to 5.6, Vacuum degree 720
Concentrate to Brix 15 at mmHg, temperature 40 ° C,
The concentrated liquid was dried to obtain a dry powder. The yield of the dry powder was about 19.6% by weight based on the dried oolong tea leaves.
【００１５】得られた乾燥粉末は、水に溶かすと暗褐色
の水色となり、その味は弱い渋味と甘味を持っていた。
また、緑茶カテキンに比較して舌の味覚神経への収斂性
の刺激は極めて弱かった。The resulting dry powder had a dark brown light blue color when dissolved in water, and its taste had a weak astringency and sweetness.
The astringent stimulation of the taste nerve of the tongue was much weaker than that of green tea catechin.
【００１６】（臨床試験１）被検者は、２１歳の女性で
あり、生後半年ぐらいでアトピー性皮膚炎と診断され、
顔・首・手・腕・膝に発症しこれらの部位にステロイド
軟膏を塗布していたが、炎症抑制効果は一過性で長年の
ステロイド外用剤の使用によりステロイド皮膚症の状態
であった。そこで、被検者に対し、ステロイドの離脱療
法とともに、上記製造方法によって得られた乾燥粉末を
Ｂｒｉｘ０．０５に希釈した湯で１日１回・５週間湯浴
したところ、皮膚の肥厚・かさつき感・つっぱり感・発
疹などがなくなり、皮膚がしっとりし、きめ細やかにな
りそう痒感もなくなった。またその後も、頑固でしつこ
いステロイド皮膚症の管理にも有効であった。(Clinical Study 1) The subject was a 21-year-old woman, who was diagnosed with atopic dermatitis in the latter half of her life.
Although it developed on the face, neck, hands, arms, and knees and steroid ointment was applied to these parts, the inflammation-suppressing effect was transient, and steroid dermatosis was present due to long-term use of topical steroids. Therefore, when a dry powder obtained by the above-mentioned manufacturing method was bathed in hot water diluted with Brix 0.05 once a day for 5 weeks, along with steroid withdrawal therapy, skin thickening and bulkiness were observed. The sensation, tightness and rash disappeared, the skin became moist, and the itchiness that was likely to be fine-grained disappeared. After that, it was also effective in the management of stubborn and persistent steroid dermatosis.
【００１７】（臨床試験２）被検者は、２０歳の女性で
あって、２歳頃にアトピー性皮膚炎と診断されたが症状
は殆ど無く、１６歳の頃から手や顔などにアトピー性の
皮膚炎が発症し、ステロイド軟膏の塗布を開始した。し
かし、炎症抑制効果は一過性であり、患部の症状はあか
みが増してそれに伴い熱を帯びるようにもなり、ステロ
イド皮膚症の状態であった。その後ステロイド軟膏の使
用を中止したが、症状は更に進んだ状態であった。そこ
で、被検者に対し、ステロイドの離脱療法とともに、上
記製造方法によって得られた乾燥粉末をＢｒｉｘ０．０
５に希釈した湯で、１日１回・５週間湯浴したところ、
皮膚の肥厚・かさつき感・つっぱり感・発疹などが改善
され、更に８週間後には皮膚がしっとりし、きめ細やか
になりそう痒感もなくなり皮膚の病変が観察できなくな
った。またその後も、頑固でしつこいステロイド皮膚症
の管理に有効であった。(Clinical study 2) The subject was a 20-year-old woman, who had been diagnosed with atopic dermatitis at about 2 years old, but had almost no symptoms, and from about 16 years atopy on her hands, face, etc. The dermatitis developed and the application of steroid ointment was started. However, the inflammation-suppressing effect was transient, and the symptom of the affected area became more tingly and became more feverish, resulting in steroid dermatosis. After that, the use of steroid ointment was stopped, but the symptom was in a more advanced state. Therefore, the dry powder obtained by the above-described manufacturing method was applied to a subject together with steroid withdrawal therapy by Brix0.0.
After bathing in hot water diluted to 5 once a day for 5 weeks,
The thickening, bulkiness, tightness, rash, etc. of the skin were improved, and after 8 weeks, the skin became moist, and the itching sensation became fine, and lesions on the skin could not be observed. After that, it was effective for the management of stubborn and persistent steroid dermatosis.
【００１８】（臨床試験３）被検者は、２９歳の男性で
あって、中学１年時にアトピー性皮膚炎と診断され、通
院を始め、患部乃至全身にステロイドホルモン剤を塗布
する治療を行い、２０歳時には発疹が減少した。以来こ
のステロイド剤を使用していたが、ステロイド皮膚症と
なりステロイド剤依存状態となっていたため、平成元年
にこの薬剤の使用を中止し、亜鉛華軟膏の使用に切り替
えた。しかし、そう痒感を押さえるのみであった。そこ
で、被検者に対し、上記製造方法によって得られた乾燥
粉末をＢｒｉｘ０．０２に希釈したお湯で１日１回・５
週間湯浴したところ、発疹が減少し、そう痒感が改善さ
れ肌のきめも細かくなった。またその後も、ステロイド
皮膚症状の如き皮膚の肥厚・かさつき感・つっぱり感・
発疹などの再発は確認されなかった。(Clinical Trial 3) A 29-year-old man was diagnosed with atopic dermatitis at the first year of junior high school, and he began to visit the hospital and was treated by applying a steroid hormone drug to the affected area or the whole body. At the age of 20, the rash decreased. Since then, he has been using this steroid drug, but since he had developed steroid dermatosis and had become addicted to steroid drugs, he discontinued the use of this drug in 1989 and switched to zinc flower ointment. However, it only suppressed the itching sensation. Therefore, the dry powder obtained by the above manufacturing method was diluted with hot water diluted with Brix 0.02 once a day for 5 times.
After taking a hot bath for a week, the rash decreased, the itching sensation improved, and the skin texture became fine. Also after that, skin thickening, bulkiness, tightness, such as steroid skin symptoms,
No recurrence such as a rash was confirmed.
【００１９】また、本発明のステロイド皮膚症治療剤を
同じくお湯に溶かしてＢｒｉｘ０．０２〜０．５の溶液
を調整し、それを浴槽に満たして沐浴を数日から数週間
継続することによりステロイド皮膚症の頑固なそう痒及
び皮疹が軽減し、より快適な日常管理が可能となったこ
と、さらにまた初期のアトピー性皮膚炎によるそう痒及
び皮疹に対しても臨床効果が確認された。The steroid dermatosis therapeutic agent of the present invention is also dissolved in hot water to prepare a solution of Brix 0.02 to 0.5, which is filled in a bath and the bath is continued for several days to several weeks. The stubborn pruritus and rash of dermatosis were alleviated, and more comfortable daily management became possible, and the clinical effect was also confirmed against pruritus and rash caused by early atopic dermatitis.
【００２０】[0020]
【発明の効果】本発明によれば、入手容易かつ長年日常
的に飲用され特に合成物に比較して安全性が高い利点を
有する茶、特に烏龍茶を原料として、アトピー性皮膚炎
を基礎疾患として今日その治療が困難を極めているステ
ロイド皮膚症のかゆみと発疹の症状軽減にこれまでにな
い効果を持つステロイド皮膚症治療剤を提供することが
できる。さらに、基礎疾患のアトピー性皮膚炎治療剤と
しても提供可能である。INDUSTRIAL APPLICABILITY According to the present invention, tea, which has the advantage of being easily available and consumed on a daily basis for many years and having a particularly high safety as compared with synthetic products, particularly oolong tea, is used as a basic disease with atopic dermatitis. It is possible to provide a therapeutic agent for steroid dermatosis having an unprecedented effect on alleviating the symptoms of itch and rash of steroid dermatosis, which is extremely difficult to treat today. Further, it can be provided as a therapeutic agent for atopic dermatitis of underlying diseases.
─────────────────────────────────────────────────────
─────────────────────────────────────────────────── ───
【手続補正書】[Procedure amendment]
【提出日】平成６年６月２８日[Submission date] June 28, 1994
【手続補正１】[Procedure Amendment 1]
【補正対象書類名】明細書[Document name to be amended] Statement
【補正対象項目名】００１１[Correction target item name] 0011
【補正方法】変更[Correction method] Change
【補正内容】[Correction content]
【００１１】ステロイド皮膚症治療剤の製造方法のさら
に好ましい一例は、烏龍茶葉を自然乾燥させて約３０〜
５０％の水分を除き、ついで数時間攪拌を行った後、釜
で茶葉をいり、揉みながら再び乾燥させて得られた烏龍
茶葉を約１０〜２０倍量の約５０〜１００℃の脱イオン
水で約５〜３０分間抽出し、この抽出物を濾過して不溶
物を除去した後、適宜量のアスコルビン酸を加えてＰＨ
５．０程度に調製し、これを約４０〜６０℃で減圧濃縮
してＢｒｉｘ約１０〜２０の濃縮液とするか、或いはさ
らに乾燥させて乾燥粉末とする。A more preferred example of the method for producing a therapeutic agent for steroid dermatosis is to dry oolong tea leaves by about 30 to 30% by natural drying.
After removing 50% of water and then stirring for several hours, the tea leaves are put in a pot and dried again while rubbing to obtain oolong tea leaves, which is about 10 to 20 times the amount of deionized water at about 50 to 100 ° C. After about 5 to 30 minutes, the extract is filtered to remove the insoluble matter, and an appropriate amount of ascorbic acid is added to add PH.
It is adjusted to about 5.0 and concentrated under reduced pressure at about 40 to 60 ° C. to obtain a concentrated solution of Brix of about 10 to 20, or further dried to obtain a dry powder.
【手続補正２】[Procedure Amendment 2]
【補正対象書類名】明細書[Document name to be amended] Statement
【補正対象項目名】００１２[Correction target item name] 0012
【補正方法】変更[Correction method] Change
【補正内容】[Correction content]
【００１２】また、本発明のステロイド皮膚症治療剤
は、上記のように乾燥粉末としたものをそのまま湯浴用
として湯に溶かして用いることもできるが、そのほか適
当な液体単体に溶解させるか若しくは分散させるか又は
適当な粉末単体と混合するか若しくはこれに吸着させ、
所要の場合はさらにこれらに賦形剤、結合剤，崩壊剤，
滑沢剤，安定剤，矯味矯臭剤等を添加するなどして、ハ
ップ剤、軟こう剤若しくは坐薬などによる非経口投与用
として、或いは錠剤、カプセル剤、か粒剤、散剤若しく
はシロップ剤などによる経口投与用としても用いること
ができる。Further, the steroid dermatosis therapeutic agent of the present invention can be used as a dry powder as described above by dissolving it in hot water as it is, or by dissolving or dispersing it in a suitable liquid simple substance. Or mixed with a suitable powder or adsorbed on it,
If necessary, these may be further added with excipients, binders, disintegrants,
Lubricants, stabilizers, flavoring agents, etc. may be added for parenteral administration such as suppositories, ointments or suppositories, or orally by tablets, capsules, granules, powders or syrups. It can also be used for administration.
───────────────────────────────────────────────────── フロントページの続き (72)発明者 福井 安彦 東京都千代田区九段南３−５−５ 医療法 人社団栄福会クリニック・フクイ内 (72)発明者 福井 和彦 東京都千代田区九段南３−５−５ 医療法 人社団栄福会クリニック・フクイ内 ─────────────────────────────────────────────────── ─── Continuation of the front page (72) Inventor Yasuhiko Fukui 3-5-5, Kudan Minami, Chiyoda-ku, Tokyo Medical Law Entrepreneur Eifukukai Clinic Fukui (72) Inventor, Kazuhiko Fukui 3-Kandan Minami, Chiyoda-ku, Tokyo 5-5 Medical Law Inside Efukukai Clinic Fukui
Claims (11)
膚症治療剤。1. A therapeutic agent for steroid dermatosis, which comprises a tea extract as an active ingredient.
茶である請求項１記載のステロイド皮膚症治療剤。2. The therapeutic agent for steroid dermatosis according to claim 1, wherein the tea is fermented tea, semi-fermented tea or unfermented tea.
のステロイド皮膚症治療剤。3. The therapeutic agent for steroid dermatosis according to claim 1, wherein the tea is oolong tea.
る請求項１，２，３のいずれかに記載のステロイド皮膚
症治療剤。4. The therapeutic agent for steroid dermatosis according to claim 1, wherein the tea extract is a water or hot water extract.
水で抽出して得られた抽出物である請求項１，２，３，
４のいずれかに記載のステロイド皮膚症治療剤。5. The tea extract is an extract obtained by extraction with warm water at 50 to 100 ° C.
The therapeutic agent for steroid dermatosis according to any one of 4 above.
膚症治療剤。6. A therapeutic agent for steroid dermatosis containing tannins as a main component.
を主成分とするステロイド皮膚症治療剤。7. The oolong tea tannin (oolong tannin)
A remedy for steroid dermatosis containing as a main component.
乾燥させて茶葉水分の約３０〜５０％を除き、ついで数
時間撹拌を行った後、釜で茶葉をいり、揉みながら乾燥
させ、これを水乃至熱水で抽出したことを特徴とするス
テロイド皮膚症治療剤の製造方法。8. Fermented tea leaves, semi-fermented tea leaves or unfermented tea leaves are removed to remove about 30 to 50% of the water content of the tea leaves, and after stirring for several hours, the tea leaves are put in a pot and dried while rubbing, A method for producing a therapeutic agent for steroid dermatosis, which comprises extracting this with water or hot water.
たことを特徴とする請求項８記載のステロイド皮膚症治
療剤の製造方法。9. The method for producing a therapeutic agent for steroid dermatosis according to claim 8, wherein the tea leaves are extracted with warm water at 50 to 100 ° C.
を乾燥して得られた茶葉を、水乃至熱水で抽出し、得ら
れた抽出物を濾過して不溶物を除いた後、この濾過液を
低酸性域に調整し、これを減圧濃縮して濃縮液とする
か、或いは濾過液を乾燥させて乾燥粉末として得るステ
ロイド皮膚症治療剤の製造方法。10. Tea leaves obtained by drying fermented tea leaves, semi-fermented tea leaves or unfermented tea leaves are extracted with water or hot water, the obtained extract is filtered to remove insoluble matter, and A method for producing a therapeutic agent for steroid dermatosis, which comprises adjusting the filtrate to a low acidic region and concentrating it under reduced pressure to obtain a concentrated solution or drying the filtrate to obtain a dry powder.
０％の水分を除き、ついで数時間攪拌を行った後、釜で
茶葉をいり、揉みながら再び乾燥させて得られた烏龍茶
葉を約１０〜２０倍量の約５０〜１００℃の脱イオン水
で約５〜３０分間抽出し、この抽出物を濾過して不溶物
を除去した後、適宜量のアスコルビン酸を加えてＰＨ
５．０程度に調製し、これを約４０〜６０℃で減圧濃縮
してＢｒｉｘ約１０〜２０の濃縮液とするか、或いはさ
らに乾燥させて乾燥粉末として得るステロイド皮膚症治
療剤の製造方法。11. Oolong tea leaves are naturally dried to about 30-5.
After removing 0% of water and stirring for several hours, put tea leaves in a pot and dry again while rubbing them to obtain oolong tea leaves, which is about 10 to 20 times the amount of deionized water at about 50 to 100 ° C. After about 5 to 30 minutes, the extract is filtered to remove the insoluble matter, and an appropriate amount of ascorbic acid is added to add PH.
A method for producing a therapeutic agent for steroid dermatosis, which is prepared to about 5.0 and concentrated under reduced pressure at about 40 to 60 ° C. to give a concentrated solution of Brix of about 10 to 20, or further dried to obtain a dry powder.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP6134675A JPH083053A (en) | 1994-06-16 | 1994-06-16 | Therapeutic agent for steroid dermatosis and its production |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP6134675A JPH083053A (en) | 1994-06-16 | 1994-06-16 | Therapeutic agent for steroid dermatosis and its production |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JPH083053A true JPH083053A (en) | 1996-01-09 |
Family
ID=15133944
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP6134675A Pending JPH083053A (en) | 1994-06-16 | 1994-06-16 | Therapeutic agent for steroid dermatosis and its production |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPH083053A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0853943A1 (en) * | 1996-12-19 | 1998-07-22 | Suntory Limited | Antiallergic agent |
-
1994
- 1994-06-16 JP JP6134675A patent/JPH083053A/en active Pending
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0853943A1 (en) * | 1996-12-19 | 1998-07-22 | Suntory Limited | Antiallergic agent |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US7205009B2 (en) | Composition for treating hair and scalp and method for preparing same | |
| CN110354204A (en) | It is a kind of to have effects that the composition of improving eyesight and its preparation, application method | |
| CN111281966B (en) | Composition containing earthworm protein and preparation method and application thereof | |
| KR20130014766A (en) | Oriental medicine composition for curing rhinitis in children and manufacturing method thereof | |
| CN103877247B (en) | Medicine being used for the treatment of decubital ulcer and preparation method thereof | |
| CN105213256A (en) | A kind of Shu Min dispels red toner/smoothing toner and preparation method thereof | |
| JP2000014354A (en) | Composition having anti-allergic or anti-inflammatory action | |
| CN111097029A (en) | Health care product for assisting gout and preparation method thereof | |
| CN110327401A (en) | Treat amblyopia and the Chinese medicinal plaster of myopia and preparation method thereof | |
| JPH083053A (en) | Therapeutic agent for steroid dermatosis and its production | |
| RU2044547C1 (en) | Composition for prevention and treatment of malignant tumors | |
| CN1434717A (en) | Medicine for treating obesity and method of producing and use thereof | |
| KR20030023297A (en) | Composition having improvement effect of the menopausal disorders | |
| CN113144032A (en) | Traditional Chinese medicine ointment for treating child anorexia and preparation method thereof | |
| CN111513157A (en) | Health tea containing medlar and cassia seed and preparation method thereof | |
| CN114010690B (en) | Traditional Chinese medicine composition for treating leucoderma and application thereof | |
| CN115414427B (en) | Traditional Chinese medicine composition for treating chronic skin pruritus and preparation method and application thereof | |
| CN102784226A (en) | External Chinese medicine preparation for realizing postoperative analgesia and promoting wound healing and preparation method of external Chinese medicine preparation | |
| JP2004352680A (en) | Composition for treatment of allergic disease | |
| CN106620438A (en) | Pharmaceutical composition for treating infancy hemangioma | |
| CN104666502A (en) | Traditional Chinese medicine composition for treating eczemas and preparation method for traditional Chinese medicine composition | |
| CN107260833B (en) | A Chinese medicinal composition for treating acne, and preparation method thereof | |
| CN105106600A (en) | Composition for promoting postoperation healing of brain trauma caused by car accidents and preparing method | |
| CN113209255A (en) | Pharmaceutical composition for regulating immunity balance and application thereof | |
| CN117180377A (en) | Traditional Chinese medicine deodorant antiperspirant and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20040127 |